免疫系统
浆液性液体
癌症研究
肿瘤微环境
输卵管
生物
癌变
卵巢癌
卵巢癌
癌症
免疫学
医学
病理
遗传学
解剖
作者
Tanjina Kader,Jia‐Ren Lin,Clemens B. Hug,Shannon Coy,Yu-An Chen,Ino de Bruijn,Natalie Shih,Euihye Jung,Roxanne J. Pelletier,Mariana Lopez Leon,Gabriel Mingo,Dalia K. Omran,Jong Suk Lee,Clarence Yapp,Baby A. Satravada,Ritika Kundra,Yilin Xu,Sabrina Chan,Juliann B. Tefft,Jeremy L. Muhlich
出处
期刊:
[Cold Spring Harbor Laboratory]
日期:2024-09-27
被引量:3
标识
DOI:10.1101/2024.09.25.615007
摘要
ABSTRACT High-Grade Serous Ovarian Cancer (HGSOC) originates from fallopian tube (FT) precursors. However, the molecular changes that occur as precancerous lesions progress to HGSOC are not well understood. To address this, we integrated high-plex imaging and spatial transcriptomics to analyze human tissue samples at different stages of HGSOC development, including p53 signatures, serous tubal intraepithelial carcinomas (STIC), and invasive HGSOC. Our findings reveal immune modulating mechanisms within precursor epithelium, characterized by chromosomal instability, persistent interferon (IFN) signaling, and dysregulated innate and adaptive immunity. FT precursors display elevated expression of MHC-class I, including HLA-E, and IFN-stimulated genes, typically linked to later-stage tumorigenesis. These molecular alterations coincide with progressive shifts in the tumor microenvironment, transitioning from immune surveillance in early STICs to immune suppression in advanced STICs and cancer. These insights identify potential biomarkers and therapeutic targets for HGSOC interception and clarify the molecular transitions from precancer to cancer. STATEMENT OF SIGNIFICANCE This study maps the immune response in fallopian tube precursors of high-grade serous ovarian cancer, highlighting localized interferon signaling, CIN, and competing immune surveillance and suppression along the progression axis. It provides an explorable public spatial profiling atlas for investigating precancer mechanisms, biomarkers, and early detection and interception strategies.
科研通智能强力驱动
Strongly Powered by AbleSci AI